These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27415130)

  • 1. Seeking an objective diagnosis of depression.
    Bilello JA
    Biomark Med; 2016 Aug; 10(8):861-75. PubMed ID: 27415130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis of depression: current and emerging methods.
    Smith KM; Renshaw PF; Bilello J
    Compr Psychiatry; 2013 Jan; 54(1):1-6. PubMed ID: 22901834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energy metabolism in major depressive disorder: Recent advances from omics technologies and imaging.
    Gu X; Ke S; Wang Q; Zhuang T; Xia C; Xu Y; Yang L; Zhou M
    Biomed Pharmacother; 2021 Sep; 141():111869. PubMed ID: 34225015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies.
    Al Shweiki MR; Oeckl P; Steinacker P; Hengerer B; Schönfeldt-Lecuona C; Otto M
    Expert Rev Proteomics; 2017 Jun; 14(6):499-514. PubMed ID: 28562112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population.
    Kamat SA; Rajagopalan K; Pethick N; Willey V; Bullano M; Hassan M
    J Manag Care Pharm; 2008 Sep; 14(7):631-42. PubMed ID: 18774873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in biomarkers of major depressive disorder.
    Huang TL; Lin CC
    Adv Clin Chem; 2015; 68():177-204. PubMed ID: 25858873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder.
    Martins-de-Souza D
    Dialogues Clin Neurosci; 2014 Mar; 16(1):63-73. PubMed ID: 24733971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders.
    Preece RL; Han SYS; Bahn S
    Expert Rev Proteomics; 2018 Apr; 15(4):325-340. PubMed ID: 29466886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent Urinary Metabolic Phenotypes between Major Depressive Disorder and Bipolar Disorder Identified by a Combined GC-MS and NMR Spectroscopic Metabonomic Approach.
    Chen JJ; Zhou CJ; Liu Z; Fu YY; Zheng P; Yang DY; Li Q; Mu J; Wei YD; Zhou JJ; Huang H; Xie P
    J Proteome Res; 2015 Aug; 14(8):3382-9. PubMed ID: 26168936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise of biomarkers in diagnosing major depression in primary care: the present and future.
    Redei EE; Mehta NS
    Curr Psychiatry Rep; 2015 Aug; 17(8):601. PubMed ID: 26081681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.
    Gadad BS; Jha MK; Czysz A; Furman JL; Mayes TL; Emslie MP; Trivedi MH
    J Affect Disord; 2018 Jun; 233():3-14. PubMed ID: 28709695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents.
    Zhou X; Liu L; Lan X; Cohen D; Zhang Y; Ravindran AV; Yuan S; Zheng P; Coghill D; Yang L; Hetrick SE; Jiang X; Benoliel JJ; Cipriani A; Xie P
    Mol Psychiatry; 2019 Oct; 24(10):1478-1488. PubMed ID: 29679072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in major depressive disorder: the role of mass spectrometry.
    Woods AG; Iosifescu DV; Darie CC
    Adv Exp Med Biol; 2014; 806():545-60. PubMed ID: 24952202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential biomarker panels for identification of Major Depressive Disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis.
    Ding X; Yang S; Li W; Liu Y; Li Z; Zhang Y; Li L; Liu S
    PLoS One; 2014; 9(5):e97479. PubMed ID: 24870353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential urinary metabolites related with the severity of major depressive disorder.
    Chen JJ; Zhou CJ; Zheng P; Cheng K; Wang HY; Li J; Zeng L; Xie P
    Behav Brain Res; 2017 Aug; 332():280-287. PubMed ID: 28624318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC-MS-based metabonomics.
    Zheng P; Chen JJ; Zhou CJ; Zeng L; Li KW; Sun L; Liu ML; Zhu D; Liang ZH; Xie P
    Transl Psychiatry; 2016 Nov; 6(11):e955. PubMed ID: 27845778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments.
    Suseelan S; Pinna G
    Adv Clin Chem; 2023; 112():1-67. PubMed ID: 36642481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Biomarkers in Major Depressive Disorder: An Update.
    Woods AG; Wormwood KL; Iosifescu DV; Murrough J; Darie CC
    Adv Exp Med Biol; 2019; 1140():585-600. PubMed ID: 31347073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive disorders: a post hoc analysis.
    Rakofsky JJ; Schettler PJ; Kinkead BL; Frank E; Judd LL; Kupfer DJ; Rush AJ; Thase ME; Yonkers KA; Rapaport MH
    J Clin Psychiatry; 2013 Nov; 74(11):1084-91. PubMed ID: 24330894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode.
    Karlović D; Serretti A; Jevtović S; Vrkić N; Serić V; Peleš AM
    J Psychiatr Res; 2013 Feb; 47(2):162-7. PubMed ID: 23102630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.